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biotics seemed to be promising. Probiotics are living or-
ganisms which, when ingested in certain numbers, exert 
health benefits beyond inherent basic nutrition  [7] . It is 
well known that specific bacteria strains have numerous 
positive effects in the gastrointestinal tract. Probiotics re-
duce the adherence of pathogen bacteria on the epithelial 
cells and thus the ability of pathogen bacterial transloca-
tions. Probiotics can control the growth of pathogen bac-
teria by stimulating the secretion of bacteriocins and de-
fensins, modulate signal transduction (e.g. NF-  B) and 
influence the innate/adaptive immune system (e.g. IgA 
secretion). Therefore, the beneficial effects of probiotics 
in IBS could be explained by increasing the mass of ben-
eficial bacteria in the large bowel, decreasing a bacterial 
overgrowth in the small bowel and reversing the imbal-
ance between the pro- and anti-inflammatory cytokines. 
Recently it was also demonstrated that some lactobacilli 
strains may modulate intestinal pain attacks by inducing 
the expression of   -opioid and cannabinoid receptors in 
the intestinal epithelial cells  [8] . 
 For IBS treatment many good clinical studies using 
mainly lactobacilli and bifidobacteria alone or in combi-
nation were published. Nineteen randomized controlled 
trials with 1,650 patients were recently analyzed in a sys-
temic review  [9] . In 10 randomized controlled trials (918 
patients) the outcome was analyzed as a dichotomous 
variable and showed that probiotics were significantly 
better than placebo. Fifteen randomized controlled trials 
(1,351 patients) assessed improvement in IBS score as a 
continuous outcome and again showed a significant ben-
 Irritable bowel syndrome (IBS) is one of the most fre-
quent gastrointestinal problems (10–20% of the adult 
population). IBS is characterized by abdominal pain, ex-
cessive flatus, bloating and an altered intestinal motility 
pattern for which no structural abnormalities can be 
found  [1] . The diagnosis is made clinically by exclusion of 
an organic disease using the Rome III criteria. 
 The main theories to explain the pathophysiology of 
IBS include alteration in the visceral perception, intesti-
nal microbiota, motility, gut epithelium and immune 
function. It seems that a dysregulated interaction be-
tween the intestinal bacteria, the gut barrier and the in-
testinal immune system play a role  [2] . Patients with IBS 
have a different composition of intestinal bacteria com-
pared to healthy controls  [3] . A nonspecific microscopic 
inflammation with increased mast cells and neutrophiles 
were found in mucosal biopsies  [4] . There are specula-
tions that IBS symptoms may result from cytokine or me-
diator secretion by these inflammatory cells. Increased 
production of proinflammatory and decreased produc-
tion of anti-inflammatory cytokines were in fact demon-
strated  [5, 6] . In addition, a low-grade inflammatory in-
filtration and activation of mast cells in proximity to 
nerves in the colonic mucosa were found and may be in-
volved in the pathogenesis of pain episodes.
 These new views in the pathogenesis of IBS changed 
the treatment approach to influence the composition of 
the gut microbiota and to stop the inflammatory process 
and to interfere in the dysregulated intestinal immune 
system. Among several treatment options, the use of pro-
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efit for probiotics. There was a significant heterogeneity 
for both calculations. This review demonstrated only a 
trend for lactobacilli and bifidobacteria but a significant 
improvement for different probiotic combinations. 
 In general, it appears that probiotics are effective in 
IBS. However, looking on single trials, it seems that pro-
biotics are more effective on single symptoms than on the 
entire IBS. The specificity of probiotics was demonstrat-
ed by O’Mahony et al.  [5] .  Lactobacillus salivarius or  Bi-
fidobacterium infantis in malted milk drinks were com-
pared, but only B. infantis was able to alleviate IBS symp-
toms. This was associated with a normalization of the 
ratio of an anti-inflammatory to a proinflammatory cy-
tokine ratio (IL-10/IL-12), suggesting an immune-modu-
lating role for B. infantis.  
 Several studies with  B. lactis DN-173010 in patients 
with IBS or abdominal discomfort were published. This 
strain is interesting. In addition to the known probiotic 
effects, there is acceleration in slow colonic transit  [10–
12] . In a double-blind, controlled trial with 267 constipat-
ed-predominant IBS patients, Guyonnet et al.  [13] found 
a significant effect on discomfort using the health-related 
quality of life score. In the subgroup of constipated pa-
tients, also the stool frequency improved significantly. 
These results were confirmed in 2 large trials including 
360 and 253 women with IBS-like symptoms. In both 
studies, a significant improvement on global symptoms 
 [14, 15] and bloating  [14] was demonstrated. 
 In conclusion, the concept of using probiotics in IBS 
patients is interesting and it appears that certain probiot-
ics strains are efficacious on several symptoms. Overall, 
the results from all the published studies are difficult to 
compare because of variation in the design, probiotics 
strains used, doses administrated and formulation. There 
is still a need for further studies to determine the most 
effective species and strain, the right doses and to clarify 
whether a combination is better than a single strain.
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